ARTES Biotechnology, specialized in recombinant protein production, process and vaccine development from microbial expression systems announces a collaboration with the global pharmaceutical company Boehringer Ingelheim Animal Health.
ARTES' expression system Hansenula polymorpha is the preferred technology for affordable mass vaccination and recommended by the World Health Organization (WHO) for these purposes. In combination with ARTES' METAVAX® platform, this offers a new, unique and very economical approach to low-cost mass production of safe and effective vaccines required in the veterinary field.
"This collaboration is another milestone in expanding our vaccine development expertise", Michael Piontek, managing director of ARTES stated. "We are more than confident that our technology platform is perfectly suited for the development of safe and cost efficient vaccines that are highly relevant for the veterinary market."
"Partnering is a central part of our strategy. We are excited about this collaboration and the opportunity to develop more innovative vaccines for the animal health market," says Rolf-Dieter Günther, Head of Global Business Development and Licensing Animal Health for Boehringer Ingelheim.
About Boehringer Ingelheim
The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, Boehringer Ingelheim operates globally with 142 affiliates and a total of more than 47,400 employees. The focus of the family-owned company, founded in 1885, is researching, developing, manufacturing and marketing new medications of high therapeutic value for human and veterinary medicine.
Taking social responsibility is an important element of the corporate culture at Boehringer Ingelheim. This includes worldwide involvement in social projects, such as the initiative "Making more Health" and caring for the employees. Respect, equal opportunities and reconciling career and family form the foundation of the mutual cooperation. In everything it does, the company focuses on environmental protection and sustainability.
In 2013, Boehringer Ingelheim achieved net sales of about 14.1 billion euros. R&D expenditure corresponds to 19.5% of its net sales.
ARTES' expression system Hansenula polymorpha is the preferred technology for affordable mass vaccination and recommended by the World Health Organization (WHO) for these purposes. In combination with ARTES' METAVAX® platform, this offers a new, unique and very economical approach to low-cost mass production of safe and effective vaccines required in the veterinary field.
"This collaboration is another milestone in expanding our vaccine development expertise", Michael Piontek, managing director of ARTES stated. "We are more than confident that our technology platform is perfectly suited for the development of safe and cost efficient vaccines that are highly relevant for the veterinary market."
"Partnering is a central part of our strategy. We are excited about this collaboration and the opportunity to develop more innovative vaccines for the animal health market," says Rolf-Dieter Günther, Head of Global Business Development and Licensing Animal Health for Boehringer Ingelheim.
About Boehringer Ingelheim
The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, Boehringer Ingelheim operates globally with 142 affiliates and a total of more than 47,400 employees. The focus of the family-owned company, founded in 1885, is researching, developing, manufacturing and marketing new medications of high therapeutic value for human and veterinary medicine.
Taking social responsibility is an important element of the corporate culture at Boehringer Ingelheim. This includes worldwide involvement in social projects, such as the initiative "Making more Health" and caring for the employees. Respect, equal opportunities and reconciling career and family form the foundation of the mutual cooperation. In everything it does, the company focuses on environmental protection and sustainability.
In 2013, Boehringer Ingelheim achieved net sales of about 14.1 billion euros. R&D expenditure corresponds to 19.5% of its net sales.
